Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Assets: 2022-2025

Historic Other Non-Current Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $2.6 million.

  • Taysha Gene Therapies' Other Non-Current Assets changed negligibly% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.2 million for FY2024, which is 17.27% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Other Non-Current Assets of $2.6 million as of Q3 2025, which was down 0.00% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Other Non-Current Assets registered a high of $2.6 million during Q1 2022, and its lowest value of $2.2 million during Q4 2024.
  • Moreover, its 3-year median value for Other Non-Current Assets was $2.6 million (2025), whereas its average is $2.6 million.
  • Data for Taysha Gene Therapies' Other Non-Current Assets shows a maximum YoY fell of 17.27% (in 2024) over the last 5 years.
  • Taysha Gene Therapies' Other Non-Current Assets (Quarterly) stood at $2.6 million in 2022, then declined by 1.40% to $2.6 million in 2023, then dropped by 17.27% to $2.2 million in 2024, then remained steady at $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.6 million for Q2 2025, and $2.6 million during Q1 2025.